About Speclipse
Speclipse is a company based in Seongnam-si (South Korea) founded in 2015 was acquired by Cellreturn in November 2019. Speclipse has raised $10.55 million across 2 funding rounds from investors including Shinhan Financial Group, Mico and MiCoBioMed. Speclipse offers products and services including Spectra-Scope®, Pico-K, and Bellus-Q. Speclipse operates in a competitive market with competitors including Bruker, Metrohm, Impedimed, Rigaku and Anvajo, among others.
- Headquarter Seongnam-si, South Korea
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
- Legal Name Speclipse, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.55 M (USD)
in 2 rounds
-
Latest Funding Round
$8 M (USD), Series A
Aug 19, 2021
-
Investors
Shinhan Financial Group
& 8 more
-
Employee Count
Not available
-
Acquired by
Cellreturn
(Nov 05, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Speclipse
Speclipse offers a comprehensive portfolio of products and services, including Spectra-Scope®, Pico-K, and Bellus-Q.
Portable tool for detecting skin cancer via laser and AI analysis.
Picosecond laser for effective skin lesion removal and therapy.
Advanced laser device for precise dermatological treatments.
People of Speclipse
Unlock access to complete
Unlock access to complete
Funding Insights of Speclipse
Speclipse has successfully raised a total of $10.55M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $8 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Speclipse
Speclipse has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Shinhan Financial Group, Mico and MiCoBioMed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Financial group
|
Locked | Locked | Locked |
Investor details for Speclipse
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Speclipse
Investment portfolio details for Speclipse
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Speclipse
Detailed financials for Speclipse
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Speclipse Comparisons
Peer comparison for Speclipse
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Speclipse
Speclipse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bruker, Metrohm, Impedimed, Rigaku and Anvajo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diversified research instrument systems are manufactured and supplied.
|
|
| Locked | Locked | Locked |
Instruments for chemical analysis are developed and manufactured.
|
|
| Locked | Locked | Locked |
Technologies for non-invasive fluid status assessment and monitoring are developed.
|
|
| Locked | Locked | Locked |
XRD, XRF, SAXS, Raman, metrology, and crystallography solutions are provided.
|
|
| Locked | Locked | Locked |
Point-of-care solutions for laboratory diagnostics are provided by Anvajo.
|
Detailed competitors of Speclipse
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Speclipse
Complete news archive for Speclipse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Speclipse
Speclipse was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Speclipse is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Speclipse is a funded company, having raised a total of $10.55M across 2 funding rounds to date.
Speclipse was founded in 2015 and is based in Seongnam-si, South Korea. Molecular spectroscopy systems are offered for early-stage skin cancer detection within the medical diagnostics sector. A non-invasive tool utilizing laser spectroscopy and statistical algorithms has been developed to analyze tissue chemical composition in vivo. Operations focus on in-vivo laser technology for diagnostic applications in healthcare.
Speclipse offers Spectra-Scope®, Pico-K, and Bellus-Q.
Speclipse has 9 investors. Key investors include Shinhan Financial Group, Mico, MiCoBioMed, Mega Investment, and Signite Partners.